Compare Stocks: ABSI, PTCT, XENE, and DNTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$8.82 +0.2%	$9.26	$2.24 ▼ $12.06	$1.51B	2.42	2.92 million shs	2.13 million shs
DNTH Dianthus Therapeutics	$108.10 +0.2%	$105.23	$24.49 ▼ $117.88	$5.91B	1.24	591,895 shs	638,544 shs
PTCT PTC Therapeutics	$69.30 -2.9%	$75.80	$56.51 ▼ $90.87	$5.78B	0.55	804,196 shs	673,537 shs
XENE Xenon Pharmaceuticals	$59.75 -1.1%	$63.57	$35.60 ▼ $72.66	$5.78B	0.61	673,746 shs	459,131 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	0.00%	+1.26%	+6.27%	+37.81%	+270.59%
DNTH Dianthus Therapeutics	0.00%	+2.14%	-1.66%	+34.27%	+345.59%
PTCT PTC Therapeutics	0.00%	-1.13%	-2.19%	-2.35%	+24.75%
XENE Xenon Pharmaceuticals	0.00%	-0.40%	-7.44%	+15.50%	+53.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$8.82 +0.2%	$9.26	$2.24 ▼ $12.06	$1.51B	2.42	2.92 million shs	2.13 million shs
DNTH Dianthus Therapeutics	$108.10 +0.2%	$105.23	$24.49 ▼ $117.88	$5.91B	1.24	591,895 shs	638,544 shs
PTCT PTC Therapeutics	$69.30 -2.9%	$75.80	$56.51 ▼ $90.87	$5.78B	0.55	804,196 shs	673,537 shs
XENE Xenon Pharmaceuticals	$59.75 -1.1%	$63.57	$35.60 ▼ $72.66	$5.78B	0.61	673,746 shs	459,131 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	0.00%	+1.26%	+6.27%	+37.81%	+270.59%
DNTH Dianthus Therapeutics	0.00%	+2.14%	-1.66%	+34.27%	+345.59%
PTCT PTC Therapeutics	0.00%	-1.13%	-2.19%	-2.35%	+24.75%
XENE Xenon Pharmaceuticals	0.00%	-0.40%	-7.44%	+15.50%	+53.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSI Absci	2.78	Moderate Buy	$13.43	52.25% Upside
DNTH Dianthus Therapeutics	2.93	Moderate Buy	$126.92	17.41% Upside
PTCT PTC Therapeutics	2.64	Moderate Buy	$98.55	42.20% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$77.13	29.09% Upside

Current Analyst Ratings Breakdown

Latest ABSI, PTCT, XENE, and DNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	DNTH Dianthus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$156.00
9/1/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/17/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/14/2026	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$120.00 ➝ $122.00
8/13/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$106.00 ➝ $109.00
8/12/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/12/2026	ABSI Absci	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
8/10/2026	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$74.00
8/7/2026	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$82.00 ➝ $81.00
8/6/2026	DNTH Dianthus Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$110.00 ➝ $128.00
8/6/2026	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$130.00 ➝ $158.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSI Absci	$1.56M	969.66	N/A	N/A	$1.43 per share	6.17
DNTH Dianthus Therapeutics	$2.04M	2,896.97	N/A	N/A	$21.44 per share	5.04
PTCT PTC Therapeutics	$1.73B	3.34	$8.77 per share	7.90	($1.98) per share	-35.00
XENE Xenon Pharmaceuticals	$7.50M	770.14	N/A	N/A	$12.85 per share	4.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSI Absci	-$115.18M	-$0.80	N/A	N/A	N/A	-7,756.38%	-61.71%	-54.52%	11/16/2026 (Estimated)
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/5/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	32.54	2.14	-3.80%	-362.45%	-1.32%	11/3/2026 (Estimated)
XENE Xenon Pharmaceuticals	-$345.91M	-$4.74	N/A	N/A	N/A	N/A	-43.98%	-41.72%	11/2/2026 (Estimated)

Latest ABSI, PTCT, XENE, and DNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ABSI Absci	-$0.1910	-$0.21	-$0.0190	-$0.21	$0.92 million	$0.32 million
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSI Absci	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSI Absci	N/A	10.63	10.63
DNTH Dianthus Therapeutics	N/A	26.10	26.10
PTCT PTC Therapeutics	N/A	3.39	3.28
XENE Xenon Pharmaceuticals	N/A	21.01	21.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSI Absci	52.05%
DNTH Dianthus Therapeutics	47.53%
PTCT PTC Therapeutics	N/A
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
ABSI Absci	10.52%
DNTH Dianthus Therapeutics	3.02%
PTCT PTC Therapeutics	5.30%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSI Absci	210	171.61 million	153.56 million	Optionable
DNTH Dianthus Therapeutics	80	54.67 million	53.02 million	Optionable
PTCT PTC Therapeutics	1,410	83.46 million	79.04 million	Optionable
XENE Xenon Pharmaceuticals	210	96.67 million	93.85 million	Optionable

ABSI, PTCT, XENE, and DNTH Headlines

Recent News About These Companies

73,728 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Legal & General Group Plc

September 5 at 3:36 AM | marketbeat.com

Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care

September 4 at 5:30 PM | insidermonkey.com

Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care

September 4 at 3:42 PM | finance.yahoo.com

The Manufacturers Life Insurance Company Invests $1.75 Million in Xenon Pharmaceuticals Inc. $XENE

September 4 at 4:31 AM | marketbeat.com

Corient Private Wealth LP Invests $1.73 Million in Xenon Pharmaceuticals Inc. $XENE

September 4 at 3:43 AM | marketbeat.com

Xenon to Present at Wells Fargo Healthcare Conference

September 3 at 4:01 PM | globenewswire.com

Xenon Pharmaceuticals Inc. $XENE is Braidwell LP's 10th Largest Position

September 3 at 4:23 AM | marketbeat.com

Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $425,847.00 in Stock

September 2, 2026 | insidertrades.com

Xenon Pharmaceuticals Inc. $XENE Shares Sold by Wellington Management Group LLP

September 2, 2026 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $425,847.00 in Stock

September 1, 2026 | marketbeat.com

Headlands Technologies LLC Buys 23,074 Shares of Xenon Pharmaceuticals Inc. $XENE

September 1, 2026 | marketbeat.com

Alyeska Investment Group L.P. Has $42.11 Million Holdings in Xenon Pharmaceuticals Inc. $XENE

August 31, 2026 | marketbeat.com

Bank of New York Mellon Corp Buys Shares of 421,518 Xenon Pharmaceuticals Inc. $XENE

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Acquires New Stake in Xenon Pharmaceuticals Inc. $XENE

August 30, 2026 | marketbeat.com

Hsbc Holdings PLC Invests $9.14 Million in Xenon Pharmaceuticals Inc. $XENE

August 29, 2026 | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 28, 2026 | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 28, 2026 | globenewswire.com

What Xenon Pharmaceuticals (XENE)'s New Azetukalner Phase 3 Epilepsy Data Means For Shareholders

August 28, 2026 | finance.yahoo.com

51,345 Shares in Xenon Pharmaceuticals Inc. $XENE Acquired by Palo Alto Investors LP

August 28, 2026 | marketbeat.com

Man Group plc Acquires New Stake in Xenon Pharmaceuticals Inc. $XENE

August 28, 2026 | marketbeat.com

Cibc World Market Inc. Takes $1.21 Million Position in Xenon Pharmaceuticals Inc. $XENE

August 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI, PTCT, XENE, and DNTH Company Descriptions

Absci NASDAQ:ABSI

$8.82 +0.02 (+0.23%)

As of 09/4/2026 04:00 PM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Dianthus Therapeutics NASDAQ:DNTH

$108.10 +0.25 (+0.23%)

As of 09/4/2026 04:00 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

PTC Therapeutics NASDAQ:PTCT

$69.30 -2.10 (-2.94%)

As of 09/4/2026 04:00 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Xenon Pharmaceuticals NASDAQ:XENE

$59.75 -0.65 (-1.08%)

As of 09/4/2026 04:00 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABSI, PTCT, XENE, and DNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABSI, PTCT, XENE, and DNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABSI, PTCT, XENE, and DNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI, PTCT, XENE, and DNTH Company Descriptions

Absci NASDAQ:ABSI

Dianthus Therapeutics NASDAQ:DNTH

PTC Therapeutics NASDAQ:PTCT

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABSI, PTCT, XENE, and DNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABSI, PTCT, XENE, and DNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABSI, PTCT, XENE, and DNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI, PTCT, XENE, and DNTH Company Descriptions

Absci NASDAQ:ABSI

Dianthus Therapeutics NASDAQ:DNTH

PTC Therapeutics NASDAQ:PTCT

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools